References
- Rudiger T, Weisenburger D D, Anderson J R, Armitage J O, Diebold J, MacLennan K A, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002; 13: 140–149
- Zettl A, Lee S S, Rudiger T, Starostik P, Marino M, Kirchner T. Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol 2002; 117: 368–379
- Park B, Ryoo B, Lee J H, Kwon H C, Yang S H, Kang H J, et al. Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. Leuk Lymphoma 2007; 48: 716–722
- Schetelig J, Fetscher S, Reichle A, Berdel W E, Beguin Y, Brunet S, et al. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 2003; 88: 1272–1278
- Strupp S, Aivado M, Germing U, Gattermann N, Haas R. Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports. Leuk Lymphoma 2002; 43: 133–137
- Joly B, Frenkel V, Gaulard P, Belhadj K, El Gnaoui T, Dupuis J, et al. Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell lymphoma (AITL). Preliminary results in 9 patients treated in a single institution. Blood 2005; 106(Suppl 1), 754a (abst)
- Halene S, Zieske A, Berliner N. Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab. Nat Clin Pract Oncol 2006; 3: 165–168